Aura Biosciences Revenue vs. Price To Book
| AURA Stock | USD 8.96 0.08 0.90% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
For Aura Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aura Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aura Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aura Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aura Biosciences over time as well as its relative position and ranking within its peers.
Aura |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aura Biosciences. If investors know Aura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aura Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.73) | Return On Assets (0.30) | Return On Equity (0.51) |
The market value of Aura Biosciences is measured differently than its book value, which is the value of Aura that is recorded on the company's balance sheet. Investors also form their own opinion of Aura Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Aura Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aura Biosciences' market value can be influenced by many factors that don't directly affect Aura Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aura Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aura Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aura Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aura Biosciences Price To Book vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aura Biosciences's current stock value. Our valuation model uses many indicators to compare Aura Biosciences value to that of its competitors to determine the firm's financial worth. Aura Biosciences is currently under evaluation in revenue category among its peers. It is rated fifth in price to book category among its peers . At present, Aura Biosciences' Total Revenue is projected to stay steady based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aura Biosciences' earnings, one of the primary drivers of an investment's value.Aura Revenue vs. Competition
Aura Biosciences is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 112.32 Million. Aura Biosciences adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Aura Price To Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Aura Biosciences |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Aura Biosciences |
| = | 2.54 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Aura Price To Book Comparison
Aura Biosciences is currently under evaluation in price to book category among its peers.
Aura Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aura Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aura Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Aura Biosciences' change in net profit over the period of time. It can combine multiple indicators of Aura Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 539 K | 566 K | |
| Net Interest Income | 7 M | 7.4 M | |
| Operating Income | -85 M | -80.7 M | |
| Net Loss | -70.8 M | -67.3 M | |
| Income Before Tax | -76.3 M | -72.5 M | |
| Total Other Income Expense Net | 8.7 M | 9.2 M | |
| Net Loss | -52.9 M | -55.5 M | |
| Net Loss | -76.4 M | -72.6 M | |
| Income Tax Expense | 137 K | 143.8 K | |
| Interest Income | 7 M | 7.4 M | |
| Non Operating Income Net Other | 1.8 M | 1.8 M | |
| Change To Netincome | 7 M | 7.4 M | |
| Net Loss | (1.93) | (2.02) | |
| Income Quality | 0.84 | 1.02 | |
| Net Income Per E B T | 1.00 | 1.09 |
Aura Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aura Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aura Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aura Biosciences' important profitability drivers and their relationship over time.
Use Aura Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aura Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aura Biosciences will appreciate offsetting losses from the drop in the long position's value.Aura Biosciences Pair Trading
Aura Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Aura Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aura Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aura Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aura Biosciences to buy it.
The correlation of Aura Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aura Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aura Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aura Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aura Biosciences position
In addition to having Aura Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 479 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Aura Stock refer to our How to Trade Aura Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
To fully project Aura Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Aura Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Aura Biosciences' income statement, its balance sheet, and the statement of cash flows.